Fortress Biotech (FBIOP) Insider Trades, Congress & Funds

Smart money at a glance

Filings to Nov 13, 2026

No insider open-market trades in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.

Company insidersForm 4, 90 days: $0
CongressSTOCK Act, 180 days: None
Big funds13F, latest quarter: No large changes
Federal contractsUSAspending.gov, 12 months: No awards

Analysts

What do analysts expect?

No analyst estimates.

Questions about FBIOP filings

Are insiders buying or selling Fortress Biotech Inc Pref Series A (FBIOP) stock?

Neither. Fortress Biotech Inc Pref Series A (FBIOP) insiders filed no open-market purchases or sales in the 90 days to Nov 13, 2026, according to SEC Form 4 filings.

Which members of Congress have traded FBIOP recently?

None. No member of Congress disclosed a FBIOP trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this FBIOP smart-money data?

This summary uses filings available on Nov 13, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.

No recent filings found.

Questions about FBIOP filings

Are insiders buying or selling Fortress Biotech Inc Pref Series A (FBIOP) stock?

Neither. Fortress Biotech Inc Pref Series A (FBIOP) insiders filed no open-market purchases or sales in the 90 days to Nov 13, 2026, according to SEC Form 4 filings.

Which members of Congress have traded FBIOP recently?

None. No member of Congress disclosed a FBIOP trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this FBIOP smart-money data?

Checking federal contract awards

Unlock everything for $29/month

Unlock for $29/month

Reported Nov 13, 2026

Results versus expectations

Documents

Quarterly report10-Q Annual report10-K Every filing

Last report

Nov 13, 2026

Period ending

Sep 30, 2026

Earnings per share

Unavailable

EPS comparison unavailable

Revenue

$19.2M

SEC filing

Next report

What the street expects next

Previous reports

Quarter / reported	Earnings per share	Beat or miss	Revenue / income	Revenue vs last year
Sep 30, 2026Reported Nov 13, 2026	Not on file	No estimate	$19.2MSEC filing	+8.7%from $17.6M
Jun 30, 2026Reported Aug 13, 2026	Not on file	No estimate	$18.7MSEC filing	+14.0%from $16.4M
Mar 31, 2026Reported May 14, 2026	Not on file	No estimate	$16.0MSEC filing	+22.1%from $13.1M
Sep 30, 2025Reported Nov 13, 2026	Not on file	No estimate	$17.6MSEC filing	+20.5%from $14.6M
Jun 30, 2025Reported Aug 13, 2026	Not on file	No estimate	$16.4MSEC filing	+10.2%from $14.9M
Mar 31, 2025Reported May 14, 2026	Not on file	No estimate	$13.1MSEC filing	+0.8%from $13.0M
Sep 30, 2024Reported Nov 14, 2025	Not on file	No estimate	$14.6MSEC filing	-57.9%from $34.8M
Jun 30, 2024Reported Aug 14, 2025	Not on file	No estimate	$14.9MSEC filing	-14.3%from $17.4M

Earnings per share comes from Yahoo Finance where available, then Alpha Vantage or the company release. Revenue comes from company releases, SEC filings, Alpha Vantage or Yahoo Finance. A beat or miss needs an analyst estimate on the same basis as the reported figure, so quarters without one show none. Non-USD amounts carry their currency code.

Open: $15.85
High: $15.97
Low: $14.96
Prev close: $15.73
52-wk high: $21.43
52-wk low: $6.27
Mkt cap: $77.8M
ROE: +116.0%
Beta: 1.26
P/S: 1.2x
Profit margin: +163.3%
Op margin: -43.2%

Fundamentals

Is the business strong?

This company is profitable.

Net margin: 163.3%
Market cap: $78M

Valuation

P/S1.23

Quality

Operating margin-43.2%
ROE116.0%
ROA-7.8%

Growth

Beta1.26

Technicals

Price structure

This stock is under pressure.

Trend

Under pressure

0 / 100

RSI 14

31balanced

20D volatility

31%annualized

52-week range

$15.00

$6.27$21.43

20D support

$14.25recent floor

20D resistance

$16.98recent ceiling

Returns

5D -0.3%20D -11.2%60D -17.6%

Price vs moving averages

SMA20 -4.7%SMA50 -11.0%SMA200 -8.4%

Volume pace

0.96xvs prior 20D

Quarter / reported

Earnings per share

Beat or miss

Revenue / income

Revenue vs last year

Sep 30, 2026Nov 13, 2026

Not on file

No estimate

$19.2MSEC filing

+8.7%from $17.6M

Jun 30, 2026Aug 13, 2026

Not on file

No estimate

$18.7MSEC filing

+14.0%from $16.4M

Mar 31, 2026May 14, 2026

Not on file

No estimate

$16.0MSEC filing

+22.1%from $13.1M

Sep 30, 2025Nov 13, 2026

Not on file

No estimate

$17.6MSEC filing

+20.5%from $14.6M

Jun 30, 2025Aug 13, 2026

Not on file

No estimate

$16.4MSEC filing

+10.2%from $14.9M

Mar 31, 2025May 14, 2026

Not on file

No estimate

$13.1MSEC filing

+0.8%from $13.0M

Sep 30, 2024Nov 14, 2025

Not on file

No estimate

$14.6MSEC filing

-57.9%from $34.8M

Jun 30, 2024Aug 14, 2025

Not on file

No estimate

$14.9MSEC filing

-14.3%from $17.4M

Fortress Biotech Inc Pref Series A

Smart money at a glance

What do analysts expect?

Questions about FBIOP filings

Questions about FBIOP filings

How top traders are positioned

Unlock everything for $29/month

Results versus expectations

What the street expects next

Previous reports

Is the business strong?

Price structure

Ask it in Claude or ChatGPT.

Fortress Biotech Inc Pref Series A

Smart money at a glance

What do analysts expect?

Questions about FBIOP filings

Questions about FBIOP filings

How top traders are positioned

Unlock everything for $29/month

Results versus expectations

What the street expects next

Previous reports

Is the business strong?

Price structure

Ask it in Claude or ChatGPT.

Fortress Biotech Inc Pref Series A

Overview

Questions about FBIOP filings

Smart money

Unlock everything for $29/month

Earnings

Previous reports

Financials

Technicals

Ask it in Claude or ChatGPT.

Fortress Biotech Inc Pref Series A

Overview

Questions about FBIOP filings

Smart money

Unlock everything for $29/month

Earnings

Previous reports

Financials

Technicals

Ask it in Claude or ChatGPT.